Skip to content
    Oncology Data Advisor Logo

    News

    Research and trial news from journals we track.

    Top Stories

    Ranked by reader clicks and relevance, last 14 days.

    1. Short-Course RT With Camrelizumab Improves 3-Year Event-Free Survival in Rectal Cancer

      The Lancet OncologyTao et al

    2. Updated 2026 International Consensus on Low-Grade Serous Ovarian Carcinoma

      Gynecologic oncologyGrisham et al

    3. Pembrolizumab Plus SBRT Does Not Improve Event-Free Survival in Unresected Stage I/II NSCLC

      Journal of clinical oncology : official journal of the American Society of Clinical OncologyJabbour et al

    4. PET-Guided De-Escalation Shows 89.5% 5-Year iDFS in HER2-Positive Breast Cancer

      Nature medicinePérez-García et al

    5. Neoadjuvant Durvalumab With Chemotherapy Yields 74.6% Resection Rate in NSCLC

      Nature MedicineReck et al

    Clinical Trials

    Illustration for: Phase I ASTEROID Trial: Tolinapant Combined With Pembrolizumab in Advanced Solid Tumors
    Nature communicationsTiu et alIllustration

    Phase I ASTEROID Trial: Tolinapant Combined With Pembrolizumab in Advanced Solid Tumors

    The phase I ASTEROID trial of tolinapant with pembrolizumab in advanced solid tumors was well tolerated and yielded an overall response rate of 33%.

    Real-World Studies

    Illustration for: Immune Checkpoint Inhibitors Linked to Cystitis and Ureteritis in FAERS Analysis
    Frontiers in pharmacologyYuanyuan Zhang and Jiajin YangIllustration

    Immune Checkpoint Inhibitors Linked to Cystitis and Ureteritis in FAERS Analysis

    A FAERS analysis and 45-patient review linked immune checkpoint inhibitors to cystitis and ureteritis, with cases showing corticosteroid responsiveness.

    Stay updated

    Weekly highlights. Unsubscribe anytime.

    Guidelines & Consensus

    Illustration for: Consensus on Perioperative Management of Carcinoid Crisis in Neuroendocrine Tumours
    BJS openHallet et alIllustration

    Consensus on Perioperative Management of Carcinoid Crisis in Neuroendocrine Tumours

    An expert Delphi panel advised that somatostatin analogues are not needed as prophylaxis before NET surgery and that crisis care start with vasopressors.

    More news